Fig. 7: MIR155HG correlates with the efficacy of PD-L1 mAb therapy in LUAD patients and improves antitumor effect of PD-L1 blockade in vivo. | Cell Death Discovery

Fig. 7: MIR155HG correlates with the efficacy of PD-L1 mAb therapy in LUAD patients and improves antitumor effect of PD-L1 blockade in vivo.

From: The recruitment of CD8+ T cells through YBX1 stabilization abrogates tumor intrinsic oncogenic role of MIR155HG in lung adenocarcinoma

Fig. 7

A Correlations of MIR155HG expression with CCL5 and PD-L1 expression in LUAD from TCGA database. B Representative images of immunofluorescence in 94 LUAD patient tissue microarrays and correlations between MIR155HG, CCL5 and PD-L1. C Correlations of MIR155HG expression with CCL5 and PD-L1 expression in microarrays. D Kaplan–Meier survival curves of survival probability according to MIR155HG-related gene signature in LUAD cohorts (GSE136961, GSE13522). E Relative MIR155HG expression between response and non-response in GSE135222. F Schematic view of mice model in PBMC-transferred NCG mice with PD-L1 mAb treatment. G Tumor growth curves and tumor volumes of Vector and MIR155HG-transfected A549 cells with PD-L1 mAb treatment in PBMC-transferred NCG mice. H Graphic abstract. Results are presented as mean ± SEM, n = 5. *p < 0.05, ***p < 0.001.

Back to article page